SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-16-588016
Filing Date
2016-05-12
Accepted
2016-05-12 07:01:33
Documents
39
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d134499d10q.htm 10-Q 208138
2 EX-31.1 d134499dex311.htm EX-31.1 5776
3 EX-32.1 d134499dex321.htm EX-32.1 2998
  Complete submission text file 0001193125-16-588016.txt   1517604

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT rxii-20160331.xml EX-101.INS 223709
5 XBRL TAXONOMY EXTENSION SCHEMA rxii-20160331.xsd EX-101.SCH 19817
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rxii-20160331_cal.xml EX-101.CAL 32074
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rxii-20160331_def.xml EX-101.DEF 47583
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE rxii-20160331_lab.xml EX-101.LAB 181905
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rxii-20160331_pre.xml EX-101.PRE 121681
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
RXi Pharmaceuticals Corp (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36304 | Film No.: 161641624
SIC: 2834 Pharmaceutical Preparations